Cargando…
Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report
BACKGROUND: The role of surgery in combined modality therapy for selected stage IV oligometastatic (OM) non-small cell lung cancer (NSCLC) is still controversial. Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) significantly improved the survival in adjuvant thera...
Autores principales: | Wu, Han, Ning, Junwei, Li, Ziming, Divisi, Duilio, Rossi, Antonio, Cortellini, Alessio, Um, Sang-Won, Okuma, Yusuke, Lazzari, Chiara, Luo, Qingquan, Chen, Tianxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073747/ https://www.ncbi.nlm.nih.gov/pubmed/35529794 http://dx.doi.org/10.21037/tlcr-22-251 |
Ejemplares similares
-
Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q
por: Song, Yang, et al.
Publicado: (2020) -
Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report
por: Qin, Zhiquan, et al.
Publicado: (2023) -
Circulating tumor DNA accurately predicts disease progression and genotype alterations in postoperative adjuvant EGFR-TKI resistance: a case report
por: Zeng, Zhen, et al.
Publicado: (2022) -
Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion
por: Zheng, Yuyan, et al.
Publicado: (2020) -
Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report
por: Zhai, Xiaoqian, et al.
Publicado: (2022)